择期骨科手术前后使用奥替尼啶套装进行全身皮肤和鼻腔去定植:针对翻修手术和手术部位感染高风险患者的单中心、非盲、优效性、随机对照试验(BALGDEC试验)
本研究为单中心、非盲、优效性随机对照试验,计划纳入1000例SSI和/或伤口并发症高风险的成人择期骨科患者,随机分为去定植组(奥替尼啶洗剂每日1次和奥替尼啶鼻腔凝胶每日2-3次,共5天)和无去定植组。主要结局为术后6周内(植入物或骨手术为1年)的SSI和因术后伤口问题进行的翻修手术。假设去定植组无事件手术率为95%、对照组为90%,需2年内纳入2×474例择期骨科手术。作者认为,在高风险成人骨科患者中,术前去定植可能减少术后伤口问题,包括SSI。
要点
- 针对SSI高风险成人择期骨科患者,比较术前奥替尼啶套装去定植与无去定植。
- 主要结局为术后6周内(植入物或骨手术为1年)的SSI和因伤口问题的翻修手术。
- 样本量假设去定植组无事件手术率95% vs 对照组90%,需2×474例。
核心结论
- 在高风险成人骨科患者中,术前去定植可能减少术后伤口问题,包括SSI。
研究设计与样本
- 单中心、非盲、优效性随机对照试验,计划随机纳入1000例SSI和/或伤口并发症高风险的成人择期骨科患者。
- 高风险定义包括年龄≥80岁、慢性免疫抑制、美国麻醉医师协会评分3-4分。
- 去定植方案为奥替尼啶洗剂每日1次和奥替尼啶鼻腔凝胶每日2-3次,共5天;对照组无去定植。
- 主要结局为术后6周内(植入物或骨手术为1年)的SSI和因术后伤口问题进行的翻修手术。
- 样本量假设去定植组无事件手术率95% vs 对照组90%,需2年内纳入2×474例择期骨科手术。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The preoperative body surface and nasal decolonization may reduce the risk of surgical site infections (SSI) but yields conflicting results in the current orthopedic literature. METHODS: We perform a single-center, randomized-controlled, superiority trial in favor of the preoperative decolonization using a commercial product (octenidine® set). We will randomize a total number of 1000 adult elective orthopedic patients with a high risk for SSI and/or wound complications (age ≥ 80 years, chronic immune-suppression, American Society of Anesthesiologists score 3-4 points) between a decolonization (octenisan® wash lotion 1 × per day and octenisan® md nasal gel 2-3 × per day; during 5 days) and no decolonization. Decolonized patients will additionally fill a questionnaire regarding the practical difficulties, the completeness, and the adverse events of decolonization. The primary outcomes are SSI and revision surgeries for postoperative wound problems until 6 weeks postoperatively (or 1 year for surgeries with implants or bone). Secondary outcomes are unplanned revision surgeries for non-infectious problems and all adverse events. With 95% event-free surgeries in the decolonization arm versus 90% in the control arm, we formally need 2 × 474 elective orthopedic surgeries included during 2 years. DISCUSSION: In selected adult orthopedic patients with a high risk for SSI, the presurgical decolonization may reduce postoperative wound problems, including SSI. TRIAL REGISTRATION: ClinicalTrial.gov NCT05647252. Registered on 9 December 2022. PROTOCOL VERSION: 2 (5 December 2022).
引用
- Unterfrauner I, Bragatto-Hess N, Studhalter T, et al. General skin and nasal decolonization with octenisan® set before and after elective orthopedic surgery in selected patients at elevated risk for revision surgery and surgical site infections-a single-center, unblinded, superiority, randomized controlled trial (BALGDEC trial). Trials. 2024. PMID: 38978089. doi:10.1186/s13063-024-08173-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。